-
Carfilzomib, sold
under the
brand name Kyprolis, is an anti-cancer
medication acting as a
selective proteasome inhibitor. Chemically, it is a tetrapeptide...
-
lenalidomide or pomalidomide), and a
proteasome inhibitor (e.g., or bortezomib,
carfilzomib or ixazomib), in
combination with a
steroid (e.g., dexamethasone). While...
-
parent compound of
multiple myeloma drug
carfilzomib (Kyprolis).
Based on
successful Phase II
trials of
carfilzomib, Onyx
Pharmaceuticals acquired Proteolix...
-
ixabepilone which is an
analogue of the
natural product epothilone B and
carfilzomib which is
derived from
epoxomicin and
eravacycline derived from tetracycline...
-
reactions (≥20%)
occurring in
people treated with daratumumab/hyaluronidase,
carfilzomib, and
dexamethasone were
upper respiratory tract infections, fatigue,...
-
being studied for the
treatment of cancer.
Drugs such as bortezomib,
carfilzomib, and
ixazomib are
already approved for use in
treating multiple myeloma...
- Parkinson's-like
symptoms in rats.
Derivatives of
epoxomicin include carfilzomib. Epoxomicin,
Santa Cruz
Biotechnology Meng, L; Mohan, R; Kwok, BH; Elofsson...
- (Abemaciclib Alvocidib†
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol)...
- (Abemaciclib Alvocidib†
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol)...
- (Abemaciclib Alvocidib†
Palbociclib Ribociclib Seliciclib†) PrI
Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide)
IMPDI (Tiazofurin§) LI (Masoprocol)...
